Skip to main content
. 2018 Sep 25;9:2226. doi: 10.3389/fimmu.2018.02226

Figure 1.

Figure 1

The IL-20 family of cytokines, their shared receptors and intracellular signaling pathways and therapeutic strategies approved or under investigation. Fezakinumab inhibits IL-22. Fletikumab inhibits IL-20. ARGX-112 inhibits the IL-22RA1 subunit. JAK/TYK2 inhibitors will prevent signaling from all the IL-20 family cytokines.